OBJECTIVE: To evaluate the clinical efficacy of lorlatinib in the treatment of non-small cell lung cancer（NSCLC） based on Meta-analysis method

and to probe into the clinical manifestations

characteristics

patterns and outcomes of adverse drug reactions（ADR） induced by lorlatinib

so as to provide references for the clinical safe medication. METHODS: By retrieving CNKI

Wanfang Data

PubMed

Web of Science and other database

randomized controlled trials（RCT） on lorlatinib in the treatment of NSCLC [the lorlatinib group was given lorlatinib regimen with or without other medication

and the control group was given the first and（or） the second generation of anaplastic lymphoma kinase（ALK）-tyrosine kinase inhibitor（TKI） regimen] were enrolled for Meta-analysis

and studies on ADR induced by lorlatinib were also analyzed. RESULTS: Totally 5 eligible RCT were enrolled

including 622 patients（308 cases in the lorlatinib group

314 cases in the control group）

the objective remission rate（ORR） was used as the main outcome indicator. The results of Meta-analysis showed that the ORR of the lorlatinib group was higher than that of the control group

with statistically significant difference（OR=2.31

95%CI=1.62-3.28

P<0.000 01）

which indicated that the efficacy of lorlatinib was significant compared with the previous 2 generations of drugs.Fourteen cases of ADR induced by lorlatinib were also collected

including 6 male patients and 8 female patients; there were more patients in the age group of >60 to 70 years old

with 7 cases; most ADR occurred at 2 weeks after medication

mainly involved cardiovascular system damage and respiratory system damage; all ADR were improved after drug withdrawal and（or） symptomatic supportive treatment; 2 cases showed no improvement or aggravation of symptoms at recurrence. CONCLUSIONS: As the third generation of ALK-TKI to treat NSCLC

the level of loratinib to treat NSCLC was significantly improved. However

clinical application of lorlatinib requires strict monitoring on cholesterol and triacylglycerol levels

as well as vigilance against central nervous system damage and cross-adverse drug reactions in the early phase of drug administration.